Trials / Active Not Recruiting
Active Not RecruitingNCT05413915
Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML
A Phase 3, Multicenter, Randomized, Open-Label, Trial Evaluating the Efficacy and Safety of Asciminib Used in Consolidation With Imatinib v. Imatinib to Achieve Treatment-free Remission in Chronic Phase-Chronic Myelogenous Leukemia Patients
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 164 (estimated)
- Sponsor
- Sarit Assouline · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to establish if consolidation of imatinib-treated patients in stable DMR through the addition of asciminib, can lead to superior rates of TFR1, compared to imatinib alone in Chronic Phase-Chronic Myelogenous Leukemia patients.
Conditions
- Chronic Myeloid Leukemia
- Chronic Myeloid Leukemia, BCR/ABL-Positive
- Chronic Myeloid Leukemia in Remission
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Asciminib | Tyrosine kinase inhibitor |
| DRUG | Imatinib | Tyrosine kinase inhibitor |
Timeline
- Start date
- 2023-11-01
- Primary completion
- 2025-12-01
- Completion
- 2025-12-01
- First posted
- 2022-06-10
- Last updated
- 2025-05-21
Locations
4 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT05413915. Inclusion in this directory is not an endorsement.